# Viatris account plan

> Viatris is a global healthcare company selling generics, established brands and innovative medicines in 165 countries, with $14.25 billion 2025 net sales.

## At a glance

Viatris is a global healthcare company formed in November 2020 from Mylan and Pfizer's Upjohn Business, with global centers in Pittsburgh, Shanghai and Hyderabad. It sells generics (including complex products such as Breyna and estradiol patches), established brands such as Lipitor, Norvasc, Lyrica and Viagra, and a growing innovative medicines portfolio to pharmacies, wholesalers, payers, governments and hospitals in more than 165 countries and territories. In 2025 total revenues were $14,299.9 million (down 3%), with a net loss of $3,514.9 million after a $2.94 billion goodwill impairment and adjusted EBITDA of $4,160.0 million. It has more than 30,000 employees and 27 manufacturing, packaging and distribution sites, and is listed in the U.S.

## Business units

- **Developed Markets** (about 60% of 2025 net sales ($8,514.0 million)): North America and Europe, with brands of $4,571.2 million and generics of $3,942.8 million in 2025; products include Lipitor, Lyrica, Creon, Breyna, EpiPen and Yupelri. Net sales fell 5% in 2025 on divestitures and the Indore Impact; in Q3 2026 North American net sales grew approximately 7% on estradiol patches.
- **Greater China** (about 16% of 2025 net sales ($2,332.5 million)): Mainland China, Taiwan and Hong Kong, almost entirely branded off-patent products such as Lipitor, Norvasc and Viagra, rebalanced toward retail pharmacy and e-commerce under volume-based procurement. Net sales grew 8% in 2025 and 14% to $702.6 million in Q3 2026.
- **Emerging Markets** (about 16% of 2025 net sales ($2,210.1 million)): More than 125 countries in Asia, Africa, Eastern Europe, Latin America and the Middle East plus the HIV (ARV) franchise. Net sales fell 2% in 2025 and 7% in Q3 2026, hit by Indian supply constraints.
- **JANZ** (about 8% of 2025 net sales ($1,193.8 million)): Japan, Australia and New Zealand, where government price cuts and competition cut 2025 net sales by 11%. Launches of EFFEXOR, Spydia and WAKIX (pitolisant) are meant to return Japan to growth.

## Strategic priorities

- **2030 growth targets**: 5%-6% total revenue growth, 7%-8% adjusted EBITDA growth, 9%-10% adjusted EPS growth and more than $3 billion a year of free cash flow by 2030.
- **Enterprise-wide strategic review savings**: A workforce reduction of up to approximately 10%, with pre-tax charges of $700 million to $850 million, targeting approximately $400 million of net cost savings split between COGS and SG&A, overseen by a transformation office.
- **Innovative portfolio**: Fast-acting meloxicam (PDUFA date December 27), cenerimod and selatogrel readouts in the first half of 2027, and new launches such as Gwyn Lo and RYZUMVI; cenerimod and selatogrel peak sales are estimated at over $1 billion each.
- **Complex generics and first-to-market**: Viatris plans generics for molecules representing about 70% of a $107 billion non-biologic patent cliff (2025-2030) and expects over 100 new generic approvals this year.
- **Business development as a platform**: Targeting $1 billion-$1.5 billion of incremental revenue and $500 million of EBITDA over five years through regional licensing and small to mid-size M&A of in-market products, mainly in the U.S., Japan and China.

## Latest results

Q3 2026 total revenues were $3,749.5 million, flat against $3,759.9 million a year earlier, as new products and growth in North America and Greater China offset supply constraints in Europe and Emerging Markets. Adjusted EBITDA rose 4% to $1,195.7 million and adjusted EPS to $0.71, while the GAAP net loss was $325.3 million because of a higher tax provision. Free cash flow was $813.7 million, up 24%. 2026 guidance midpoints were raised to total revenues of $14,800 million and adjusted EBITDA of $4,500 million, excluding Pacira.

## Investments and deals

- **Pacira BioSciences acquisition**: Definitive agreement at $36.50 per share in cash, an aggregate equity value of $1.65 billion, adding EXPAREL and ZILRETTA; closing expected by end of November 2026, with more than $50 million of annual cost synergies by end of 2028.
- **Aculys Pharma**: Acquired October 15, 2025 for $35.0 million upfront for Japanese rights to pitolisant and Spydia.
- **Idorsia assets**: $350 million upfront in March 2024 for selatogrel and cenerimod, amended in February 2025 to add Asian cenerimod rights.
- **Patch capacity**: The estradiol patch plant moved to 24/7 operation, a packaging line is being added and expansion outside Vermont is under study.
- **Capital expenditure**: $378.8 million in 2025, with $350 million to $450 million expected in 2026.

## Challenges and risks

- **Indian manufacturing compliance**: The Indore warning letter and import alert bar 11 products from the U.S., and the FDA classified the Nashik plant Official Action Indicated; manufacturing there is suspended until an expected Q1 2027 restart, costing approximately $100 million of revenue per quarter.
- **Pricing pressure**: Government price reductions in Japan and Australia, volume-based procurement in China and more hospital-channel pressure expected in 2026.
- **Loss of exclusivity**: Possible mid-2027 loss of exclusivity for AMITIZA in Japan and the full-year effect of isosulfan blue's LOE are flagged as 2027 headwinds.
- **Restructuring execution**: The enterprise-wide strategic review and workforce reduction carry execution risk, alongside dependence on a few third-party API suppliers.

## What leadership says

> "we believe we have entered a new phase of sustained growth for Viatris" — Scott A. Smith, CEO, Q3 2026 earnings call, 5 November 2026

> "Our third-quarter results reflect strong execution and reinforce our confidence in the growth trajectory of our business" — Scott A. Smith, CEO, Q3 2026 earnings release, 5 November 2026

> "We've merged two companies, divested four major businesses, stabilized and returned the base business to growth" — Scott A. Smith, CEO, Investor Event 2026, March 2026

> "operational momentum across our higher-margin businesses and continued focus on cost discipline" — Paul Campbell, Interim CFO, Q3 2026 earnings release, 5 November 2026


## Where a supplier can help

- **Quality remediation in India**: The Nashik and Indore remediation challenge creates needs for quality systems, compliance consulting, validation and data-integrity tools.
- **Contract manufacturing and API supply**: Supply constraints and dependence on a few API suppliers make second-source CDMOs and API makers relevant, as does patch capacity expansion.
- **Transformation office savings**: The approximately $400 million net savings target across COGS and SG&A fits procurement, automation and shared-services providers.
- **Launch and integration support**: Launching fast-acting meloxicam, Gwyn Lo and RYZUMVI and integrating Pacira's U.S. team point to commercial, medical affairs and post-merger integration services.
- **Technology and data modernisation**: The Modernize for Sustainable Growth imperative covers technology, data and talent, an entry point for IT, analytics and HR platforms.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Viatris Inc. Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/vtrs-20251231.htm)

Annual report · 2026-02-26

- Viatris is a global healthcare company formed in November 2020 by combining Mylan with Pfizer's Upjohn Business; it supplies medicines to approximately 1 billion patients a year, operates in more than 165 countries and territories with more than 30,000 employees, 27 manufacturing, packaging and distribution sites and more than 1,400 approved molecules.
- FY2025 total revenues were $14.30 billion (down 3%, down 4% at constant currency) after 2024 divestitures and the Indore Impact (FDA warning letter and import alert at its Indore, India plant), estimated at approximately $370 million of lost revenue; net loss was $3,514.9 million, driven by a $2.94 billion goodwill impairment; adjusted EBITDA was $4,160.0 million and adjusted EPS $2.35.
- Four geographic segments: Developed Markets ($8,514.0 million net sales), Greater China ($2,332.5 million, up 8%), Emerging Markets ($2,210.1 million) and JANZ ($1,193.8 million, down 11%). Brands were $9,184.0 million of net sales and generics $5,066.4 million.
- Top products: Lipitor ($1,549.3 million), Norvasc ($709.9 million), Lyrica ($487.0 million), EpiPen Auto-Injectors ($469.7 million), Viagra ($408.2 million), Creon ($365.8 million); the top ten products were approximately 36% of net sales. Cencora alone was 11% of net sales.
- Enterprise-wide strategic review (results announced February 26, 2026): global workforce reduction of up to approximately 10%, pre-tax charges of $700 million to $850 million, and expected savings of $600 million to $700 million once fully implemented, mostly over three years.
- Three strategic imperatives: Drive Our Base Business, Fuel Our Innovative Portfolio, Modernize for Sustainable Growth (technology, data and talent). R&D expense rose to $965.9 million, mainly for selatogrel and cenerimod; five positive Phase 3 readouts in 2025 (fast-absorbing meloxicam, low dose estrogen weekly patch, MR-141 presbyopia, MR-142, EFFEXOR in Japan); Aculys Pharma acquired in October 2025 for Japan CNS assets.
- Capital: more than $1 billion returned in 2025 (about $500 million buybacks, $561 million dividends); operating cash flow $2.32 billion; capex $378.8 million with $350 million to $450 million expected in 2026; Biocon Biologics stake sold for $815 million.
- Key risks: restructuring execution, tariffs, pricing pressure (China VBP covering approximately 490 molecules, Japan and Australia price cuts), manufacturing quality (Indore remediation, mid-February 2026 fire at Nashik), customer concentration (top three customers approximately 25% of net sales) and significant indebtedness.

### [Viatris Reports Third-Quarter 2026 Financial Results (earnings release, Form 8-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000053/exhibit991-3q26earningsrel.htm)

Interim report · 2026-11-05

- Q3 2026 (quarter to September 30, published November 5, 2026): total revenues $3.75 billion, flat on a reported and operational basis; U.S. GAAP net loss $325 million, mainly from a higher income tax provision; adjusted EBITDA $1.20 billion (up 4%); adjusted EPS $0.71 (up 6%).
- By segment: Developed Markets $2,215.9 million (down 2%), Greater China $702.6 million (up 14%), Emerging Markets $529.1 million (down 7%), JANZ $287.1 million (down 6%). Brands $2,461.4 million (up 1%), generics $1,273.3 million (down 3%).
- Nine months: total revenues $11,023.3 million (up 4%, up 2% operationally), adjusted EBITDA $3,433.5 million, adjusted EPS $1.99, free cash flow $1,491.1 million.
- Adjusted gross margin 58.0% vs 56.0%; free cash flow $813.7 million in the quarter ($895 million excluding transaction and restructuring costs).
- New product revenues approximately $115 million in the quarter; approximately $450 million now expected for 2026.
- Nashik (India) plant classified Official Action Indicated by the FDA; manufacturing voluntarily suspended in October, restart expected in Q1 2027; supply constraints cost approximately $100 million of revenue in Q3 and are expected to cost approximately $100 million in Q4.
- Agreed to acquire Pacira BioSciences for $36.50 per share in cash ($1.65 billion equity value), closing expected by end of November 2026; FDA approved RYZUMVI for presbyopia, Japan approved WAKIX, Gwyn Lo launched in the U.S.
- 2026 guidance midpoints raised: total revenues $14,800 million, adjusted EBITDA $4,500 million, adjusted EPS $2.60, free cash flow excluding transaction and restructuring costs $2,300 million (all excluding Pacira); about $717 million returned to shareholders year to date.

### [Viatris Q3 2026 earnings call transcript](https://stockanalysis.com/stocks/vtrs/transcripts/726221-q3-2026/)

Executive talk · Scott A. Smith, Chief Executive Officer · 2026-11-05

- CEO Scott Smith says Viatris has "entered a new phase of sustained growth": nine-month total revenues up 2%, adjusted EBITDA up 6% and adjusted EPS up 8% operationally, with all 2026 guidance midpoints raised.
- North America net sales grew approximately 7%, led by higher-margin complex generics including estradiol patches (over 65% of North American generics net sales); patch volumes roughly doubled and the Vermont plant moved from 24/5 to 24/7 operation.
- Greater China grew approximately 10% in Q3 (16%-17% in H1); the hospital procurement policy will push growth lower in Q4, and 2027 growth is expected in the low to mid-single digit range.
- Pacira acquisition adds EXPAREL and ZILRETTA; with them the U.S. innovative medicines business is expected to exceed $1 billion of revenue in 2027; more than $50 million of annual cost synergies by end of 2028; immediately accretive to 2027 metrics, funded from cash and short-term borrowings.
- Nashik supply constraints cost approximately $100 million of Q3 revenue; gross leverage at approximately 2.9x against a 2.8x-3.2x target; $120 million of EWSR net savings on track for 2026.
- Pipeline: fast-acting meloxicam PDUFA date December 27 with launch early 2027; cenerimod and selatogrel Phase 3 readouts in H1 2027; over 100 new generic approvals this year; first-to-file for Wegovy 25 mg tablets.
- Asked whether $5 billion of EBITDA is possible in 2027, Smith said the numbers are "certainly in the ballpark", without giving 2027 guidance; 2027 headwinds include a possible mid-year Amitiza LOE in Japan.

### [Viatris Investor Event 2026 transcript (2030 targets)](https://stockanalysis.com/stocks/vtrs/transcripts/610188-investor-update/)

Executive talk · Scott A. Smith, Chief Executive Officer · 2026-03-19

- At the 2026 investor event, CEO Scott Smith set 2030 targets of 5%-6% total revenue growth, 7%-8% adjusted EBITDA growth, 9%-10% adjusted EPS growth and more than $3 billion of annual free cash flow; at least $11 billion of cash to deploy through 2030.
- Smith described three businesses: a global generics business, established brands (Lipitor, Norvasc, Celebrex, Xanax, Viagra) and a growing innovative medicines business; about 1,300 unique products and roughly 1 billion patients reached a year.
- CFO Doretta Mistras: base case of 3%-4% revenue growth and 4%-5% adjusted EBITDA growth through 2030; about $400 million of net cost savings from the enterprise-wide strategic review, split evenly between COGS and SG&A; more than $10 billion of debt reduction since 2021; gross leverage target 2.8-3.2x.
- Chief Strategy Officer Hemanth J. Varghese: business development to add $1 billion-$1.5 billion of revenue and $500 million of EBITDA over five years, prioritising in-market, high-margin branded products in specialist therapeutic areas, mainly in the U.S.; 59 regional partnering deals done last year.
- Chief Commercial Officer Corinne Le Goff: peak sales potential up to $500 million for fast-acting meloxicam, $180 million or higher for the low-dose estrogen patch, over $1 billion each for cenerimod and selatogrel; up to $300 million combined sales by 2030 from new launches in Japan; approximately 8,500 sales people.
- Chief R&D Officer Philippe Martin: cenerimod OPUS studies fully enrolled (above 70% interferon-1 high), SOS-AMI selatogrel readout around H1 2027; about 95 approvals expected in 2026, 90 of them generics.

## Questions about Viatris

### What does Viatris do?

Viatris makes and sells generics, established brands such as Lipitor and Viagra, and innovative medicines, supplying approximately 1 billion patients a year in more than 165 countries and territories.

### What is Viatris's revenue?

Total revenues were $14,299.9 million in 2025; 2026 guidance is $14,700 million to $14,900 million, excluding Pacira.

### How many employees does Viatris have?

More than 30,000 according to the 2025 10-K, before a planned workforce reduction of up to approximately 10%.

### Who leads Viatris?

Scott A. Smith is CEO, Paul Campbell is Interim CFO and Melina Higgins chairs the board.

### What is Viatris's strategy?

Drive the base business, fuel the innovative portfolio and modernize for sustainable growth, aiming for 5%-6% revenue growth and more than $3 billion of annual free cash flow by 2030.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
